INBRX-109 drug page Clinical trials

Trials with INBRX-109

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
1Recruiting
6Countries
411Planned patients

Showing 1–1 of 1

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Recruiting Phase 1 411 patients NCT03715933

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

United States, France, Italy, Netherlands and 2 more Oct 2018 – Jun 2029 Interventional

Where the recruiting trials are